Cross-Sector entity
All 1 tracked stories fall under one category: earnings. Brad Pagano is most often covered alongside AbbVie, which appears in 1 of these 1 story. Brad Pagano appears in 1 tracked Cross-Sector story from February 19, 2026. The tracked stories average 2 original sources each.
1 verified story tracked
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Brad Pagano is most often covered alongside AbbVie, which appears in 1 of these 1 story. Brad Pagano appears in 1 tracked Cross-Sector story from February 19, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Brad Pagano. Shared-story counts are live from our verified record — not editorial picks.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
